158 related articles for article (PubMed ID: 17577103)
21. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.
Lobo ED; Quinlan T; O'Brien L; Knadler MP; Heathman M
Clin Pharmacokinet; 2009; 48(3):189-97. PubMed ID: 19385712
[TBL] [Abstract][Full Text] [Related]
23. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.
Strawn JR; Prakash A; Zhang Q; Pangallo BA; Stroud CE; Cai N; Findling RL
J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):283-93. PubMed ID: 25791145
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects.
Chalon S; Pereira A; Lainey E; Vandenhende F; Watkin JG; Staner L; Granier LA
Psychopharmacology (Berl); 2005 Feb; 177(4):357-65. PubMed ID: 15290000
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.
Wernicke JF; Prakash A; Kajdasz DK; Houston J
J Diabetes Complications; 2009; 23(5):349-59. PubMed ID: 18768332
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.
Lobo ED; Loghin C; Knadler MP; Quinlan T; Zhang L; Chappell J; Lucas R; Bergstrom RF
Clin Pharmacokinet; 2008; 47(2):103-9. PubMed ID: 18193916
[TBL] [Abstract][Full Text] [Related]
27. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
[TBL] [Abstract][Full Text] [Related]
29. Short- and long-term efficacy and safety of duloxetine in women with predominant stress urinary incontinence.
Cardozo L; Lange R; Voss S; Beardsworth A; Manning M; Viktrup L; Zhao YD
Curr Med Res Opin; 2010 Feb; 26(2):253-61. PubMed ID: 19929591
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
31. How are women with SUI-symptoms treated with duloxetine in real life practice? - preliminary results from a large observational study in Germany.
Manning M; Gotsch U; Minarzyk A; Quail D; Gross A; Pages I; Methfessel HD; Michel MC
Int J Clin Pract; 2009 Dec; 63(12):1724-33. PubMed ID: 19930333
[TBL] [Abstract][Full Text] [Related]
32. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
34. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.
Raskin J; Smith TR; Wong K; Pritchett YL; D'Souza DN; Iyengar S; Wernicke JF
J Palliat Med; 2006 Feb; 9(1):29-40. PubMed ID: 16430342
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine: clinical pharmacokinetics and drug interactions.
Knadler MP; Lobo E; Chappell J; Bergstrom R
Clin Pharmacokinet; 2011 May; 50(5):281-94. PubMed ID: 21366359
[TBL] [Abstract][Full Text] [Related]
36. Duloxetine versus placebo in the treatment of stress urinary incontinence.
Norton PA; Zinner NR; Yalcin I; Bump RC;
Am J Obstet Gynecol; 2002 Jul; 187(1):40-8. PubMed ID: 12114886
[TBL] [Abstract][Full Text] [Related]
37. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine vs. placebo in patients with painful diabetic neuropathy.
Goldstein DJ; Lu Y; Detke MJ; Lee TC; Iyengar S
Pain; 2005 Jul; 116(1-2):109-18. PubMed ID: 15927394
[TBL] [Abstract][Full Text] [Related]
39. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
40. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
